TransMedics Group (TMDX) Stock Forecast, Price Target & Predictions
TMDX Stock Forecast
TransMedics Group stock forecast is as follows: an average price target of $126.75 (represents a 59.76% upside from TMDX’s last price of $79.34) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.
TMDX Price Target
The average price target for TransMedics Group (TMDX) is $126.75 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $180.00 to $45.00. This represents a potential 59.76% upside from TMDX's last price of $79.34.
TMDX Analyst Ratings
According to 9 Wall Street analysts, TransMedics Group's rating consensus is 'Buy'. The analyst rating breakdown for TMDX stock is 0 'Strong Buy' (0.00%), 7 'Buy' (77.78%), 2 'Hold' (22.22%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
TransMedics Group Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 29, 2024 | Joe Vruwink | Robert W. Baird | $150.00 | $88.70 | 69.11% | 89.06% |
| Oct 29, 2024 | Jason Mills | Canaccord Genuity | $109.00 | $126.24 | -13.66% | 37.38% |
| Oct 29, 2024 | Mike Matson | Needham | $109.00 | $126.24 | -13.66% | 37.38% |
| Oct 29, 2024 | Suraj Kalia | Oppenheimer | $125.00 | $126.24 | -0.98% | 57.55% |
| Sep 23, 2024 | David Rescott | Robert W. Baird | $200.00 | $159.50 | 25.39% | 152.08% |
| Sep 04, 2024 | Matt O'Brien | Piper Sandler | $180.00 | $158.42 | 13.62% | 126.87% |
| Aug 21, 2024 | Mike Matson | Needham | $208.00 | $166.18 | 25.17% | 162.16% |
| Aug 01, 2024 | William Plovanic | Canaccord Genuity | $169.00 | $164.02 | 3.04% | 113.01% |
| Aug 01, 2024 | Suraj Kalia | Oppenheimer | $200.00 | $142.26 | 40.59% | 152.08% |
| Jul 15, 2024 | Patrick Wood | Morgan Stanley | $145.00 | $142.19 | 1.98% | 82.76% |
The latest TransMedics Group stock forecast, released on Oct 29, 2024 by Joe Vruwink from Robert W. Baird, set a price target of $150.00, which represents a 69.11% increase from the stock price at the time of the forecast ($88.70), and a 89.06% increase from TMDX last price ($79.34).
TransMedics Group Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 4 | 6 | 12 |
| Avg Price Target | $123.25 | $145.50 | $159.67 |
| Last Closing Price | $79.34 | $79.34 | $79.34 |
| Upside/Downside | 55.34% | 83.39% | 101.25% |
In the current month, the average price target of TransMedics Group stock is $123.25, according to 4 Wall Street analysts offering twelve months forecast. The average price target represents a 55.34% increase as opposed to TransMedics Group's last price of $79.34. This month's average price target is down -15.29% compared to last quarter, and down -22.81% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 29, 2024 | William Blair | Outperform | Outperform | Hold |
| Oct 29, 2024 | Stephens | Buy | Buy | Hold |
| Oct 29, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Oct 29, 2024 | Needham | Buy | Buy | Hold |
| Oct 29, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Oct 24, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 24, 2024 | Stephens | Buy | Buy | Hold |
| Sep 05, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 04, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 26, 2024 | Canaccord Genuity | Buy | Buy | Hold |
TransMedics Group's last stock rating was published by William Blair on Oct 29, 2024. The company gave TMDX a "Outperform" rating, the same as its previous rate.
TransMedics Group Financial Forecast
TransMedics Group Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $66.43M | $52.47M | $41.55M | $31.38M | $25.68M | $20.52M | $15.88M | $9.67M | $5.37M | $8.17M | $7.05M | $7.63M | $7.09M | $3.39M | $7.53M | $6.06M | $7.21M |
| Avg Forecast | $172.55M | $161.98M | $160.54M | $143.59M | $146.93M | $139.34M | $138.61M | $123.25M | $112.75M | $115.00M | $98.84M | $83.78M | $68.49M | $49.19M | $42.42M | $37.93M | $24.45M | $18.88M | $16.27M | $9.66M | $7.51M | $6.34M | $7.42M | $7.10M | $6.06M | $5.55M | $2.75M | $7.14M | $6.97M | $6.67M |
| High Forecast | $179.12M | $168.16M | $166.66M | $149.07M | $152.53M | $144.65M | $143.89M | $125.94M | $115.84M | $115.43M | $98.84M | $86.97M | $69.81M | $49.19M | $44.04M | $39.38M | $25.38M | $18.88M | $16.27M | $9.66M | $7.51M | $6.34M | $7.42M | $7.10M | $6.06M | $5.55M | $2.75M | $7.14M | $6.97M | $6.67M |
| Low Forecast | $165.55M | $155.41M | $154.03M | $137.77M | $140.97M | $133.69M | $132.98M | $120.08M | $110.32M | $114.57M | $98.84M | $80.38M | $67.75M | $49.19M | $40.70M | $36.40M | $23.46M | $18.88M | $16.27M | $9.66M | $7.51M | $6.34M | $7.42M | $7.10M | $6.06M | $5.55M | $2.75M | $7.14M | $6.97M | $6.67M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 7 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.35% | 1.24% | 1.10% | 1.28% | 1.36% | 1.26% | 1.64% | 1.29% | 0.85% | 1.10% | 0.99% | 1.26% | 1.28% | 1.23% | 1.05% | 0.87% | 1.08% |
TransMedics Group's average Quarter revenue forecast for Dec 23 based on 4 analysts is $68.49M, with a low forecast of $67.75M, and a high forecast of $69.81M. TMDX's average Quarter revenue forecast represents a 3.11% increase compared to the company's last Quarter revenue of $66.43M (Sep 23).
TransMedics Group EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 7 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-28.34M | $1.52M | $-1.53M | $-5.69M | $-5.73M | $-10.53M | $-9.09M | $-11.21M | $-11.52M | $-9.25M | $-6.52M | $-4.90M | $-3.71M | $-7.12M | $-7.43M | $-7.75M | $-6.85M |
| Avg Forecast | $-111.96M | $-105.11M | $-104.17M | $-93.17M | $-95.34M | $-90.41M | $-89.94M | $-79.98M | $-73.16M | $-74.62M | $-64.14M | $-8.67M | $-44.44M | $-31.92M | $-27.53M | $-7.88M | $-11.15M | $-12.36M | $-10.66M | $-7.17M | $-4.92M | $-4.16M | $-4.86M | $-6.52M | $-3.97M | $-3.64M | $-1.80M | $-7.06M | $-4.56M | $-4.37M |
| High Forecast | $-107.42M | $-100.85M | $-99.95M | $-89.40M | $-91.47M | $-86.75M | $-86.29M | $-77.92M | $-71.58M | $-74.34M | $-64.14M | $-6.94M | $-43.96M | $-31.92M | $-26.41M | $-6.31M | $-8.92M | $-12.36M | $-10.66M | $-5.73M | $-4.92M | $-4.16M | $-4.86M | $-5.21M | $-3.97M | $-3.64M | $-1.80M | $-5.65M | $-4.56M | $-4.37M |
| Low Forecast | $-116.23M | $-109.11M | $-108.14M | $-96.73M | $-98.97M | $-93.86M | $-93.37M | $-81.72M | $-75.17M | $-74.90M | $-64.14M | $-10.41M | $-45.30M | $-31.92M | $-28.58M | $-9.46M | $-13.38M | $-12.36M | $-10.66M | $-8.60M | $-4.92M | $-4.16M | $-4.86M | $-7.82M | $-3.97M | $-3.64M | $-1.80M | $-8.47M | $-4.56M | $-4.37M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.89% | -0.06% | 0.19% | 0.51% | 0.46% | 0.99% | 1.27% | 2.28% | 2.77% | 1.90% | 1.00% | 1.23% | 1.02% | 3.95% | 1.05% | 1.70% | 1.57% |
2 analysts predict TMDX's average Quarter EBITDA for Sep 23 to be $-31.92M, with a high of $-31.92M and a low of $-31.92M. This is -2192.96% lower than TransMedics Group's previous annual EBITDA (Jun 23) of $1.52M.
TransMedics Group Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 7 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-25.42M | $-1.00M | $-2.64M | $-6.72M | $-7.43M | $-11.52M | $-10.56M | $-12.67M | $-12.96M | $-10.67M | $-7.92M | $-6.31M | $-5.09M | $-8.50M | $-8.85M | $-9.18M | $-8.28M |
| Avg Forecast | $22.42M | $19.50M | $21.91M | $18.25M | $15.89M | $14.91M | $16.02M | $11.15M | $6.56M | $10.47M | $7.52M | $-10.54M | $-2.47M | $-5.79M | $-4.67M | $-9.58M | $-12.61M | $-14.54M | $-12.28M | $-8.71M | $-15.19M | $-12.54M | $-9.96M | $-7.92M | $-8.78M | $-11.30M | $-14.88M | $-8.41M | $-13.76M | $-15.79M |
| High Forecast | $23.53M | $20.46M | $23.00M | $19.15M | $16.67M | $15.65M | $16.81M | $12.59M | $8.97M | $10.48M | $7.53M | $-8.43M | $-1.48M | $-5.48M | $-4.42M | $-7.66M | $-10.09M | $-14.54M | $-12.28M | $-6.97M | $-15.19M | $-12.54M | $-9.96M | $-6.33M | $-8.78M | $-11.30M | $-14.88M | $-6.73M | $-13.76M | $-15.79M |
| Low Forecast | $21.24M | $18.47M | $20.76M | $17.29M | $15.05M | $14.12M | $15.17M | $8.99M | $4.14M | $10.46M | $7.52M | $-12.65M | $-4.69M | $-6.07M | $-4.90M | $-11.50M | $-15.13M | $-14.54M | $-12.28M | $-10.45M | $-15.19M | $-12.54M | $-9.96M | $-9.50M | $-8.78M | $-11.30M | $-14.88M | $-10.09M | $-13.76M | $-15.79M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.39% | 0.21% | 0.28% | 0.53% | 0.51% | 0.94% | 1.21% | 0.83% | 1.03% | 1.07% | 1.00% | 0.72% | 0.45% | 0.57% | 1.05% | 0.67% | 0.52% |
TransMedics Group's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TMDX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
TransMedics Group SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 7 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $30.65M | $29.36M | $24.98M | $21.73M | $16.85M | $17.38M | $13.94M | $12.00M | $10.34M | $9.16M | $6.97M | $6.18M | $5.49M | $5.87M | $6.65M | $6.17M | $6.52M |
| Avg Forecast | $153.59M | $144.19M | $142.91M | $127.82M | $130.79M | $124.03M | $123.38M | $109.71M | $100.37M | $102.37M | $87.99M | $9.28M | $60.97M | $43.79M | $37.76M | $8.44M | $11.94M | $16.77M | $14.46M | $7.67M | $6.67M | $5.64M | $6.59M | $6.97M | $5.39M | $4.93M | $2.44M | $6.32M | $6.19M | $5.93M |
| High Forecast | $159.45M | $149.69M | $148.36M | $132.69M | $135.77M | $128.76M | $128.08M | $112.11M | $103.12M | $102.75M | $87.99M | $11.14M | $62.14M | $43.79M | $39.20M | $10.13M | $14.33M | $16.77M | $14.46M | $9.21M | $6.67M | $5.64M | $6.59M | $8.37M | $5.39M | $4.93M | $2.44M | $7.58M | $6.19M | $5.93M |
| Low Forecast | $147.37M | $138.34M | $137.11M | $122.64M | $125.48M | $119.00M | $118.38M | $106.89M | $98.20M | $101.98M | $87.99M | $7.43M | $60.31M | $43.79M | $36.23M | $6.75M | $9.55M | $16.77M | $14.46M | $6.14M | $6.67M | $5.64M | $6.59M | $5.58M | $5.39M | $4.93M | $2.44M | $5.06M | $6.19M | $5.93M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.70% | 0.78% | 2.96% | 1.82% | 1.00% | 1.20% | 1.82% | 1.80% | 1.83% | 1.39% | 1.00% | 1.15% | 1.11% | 2.40% | 1.05% | 1.00% | 1.10% |
TransMedics Group's average Quarter SG&A projection for Dec 23 is $60.97M, based on 4 Wall Street analysts, with a range of $60.31M to $62.14M. The forecast indicates a 98.90% rise compared to TMDX last annual SG&A of $30.65M (Sep 23).
TransMedics Group EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 7 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.78 | $-0.03 | $-0.08 | $-0.21 | $-0.25 | $-0.41 | $-0.38 | $-0.46 | $-0.47 | $-0.39 | $-0.29 | $-0.23 | $-0.19 | $-0.36 | $-0.42 | $-0.43 | $-0.39 |
| Avg Forecast | $0.63 | $0.55 | $0.61 | $0.51 | $0.45 | $0.42 | $0.45 | $0.31 | $0.18 | $0.29 | $0.21 | $-0.02 | $-0.07 | $-0.16 | $-0.13 | $-0.25 | $-0.30 | $-0.41 | $-0.35 | $-0.38 | $-0.43 | $-0.36 | $-0.28 | $-0.29 | $-0.25 | $-0.32 | $-0.42 | $-0.40 | $-0.39 | $-0.45 |
| High Forecast | $0.66 | $0.57 | $0.64 | $0.54 | $0.47 | $0.44 | $0.47 | $0.35 | $0.25 | $0.29 | $0.21 | $-0.02 | $-0.04 | $-0.15 | $-0.12 | $-0.23 | $-0.28 | $-0.41 | $-0.35 | $-0.38 | $-0.43 | $-0.36 | $-0.28 | $-0.29 | $-0.25 | $-0.32 | $-0.42 | $-0.40 | $-0.39 | $-0.45 |
| Low Forecast | $0.60 | $0.52 | $0.58 | $0.48 | $0.42 | $0.40 | $0.43 | $0.25 | $0.12 | $0.29 | $0.21 | $-0.02 | $-0.13 | $-0.17 | $-0.14 | $-0.26 | $-0.31 | $-0.41 | $-0.35 | $-0.38 | $-0.43 | $-0.36 | $-0.28 | $-0.29 | $-0.25 | $-0.32 | $-0.42 | $-0.40 | $-0.39 | $-0.45 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.81% | 0.24% | 0.33% | 0.70% | 0.61% | 1.18% | 1.00% | 1.07% | 1.32% | 1.38% | 1.00% | 0.92% | 0.59% | 0.85% | 1.06% | 1.10% | 0.87% |
According to undefined Wall Street analysts, TransMedics Group's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TMDX previous annual EPS of $NaN (undefined).
TransMedics Group Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TELA | TELA Bio | $2.89 | $12.50 | 332.53% | Buy |
| DCTH | Delcath Systems | $9.85 | $22.00 | 123.35% | Buy |
| LUNG | Pulmonx | $6.42 | $11.93 | 85.83% | Buy |
| TMDX | TransMedics Group | $79.34 | $126.75 | 59.76% | Buy |
| INMD | InMode | $18.49 | $27.50 | 48.73% | Hold |
| NPCE | NeuroPace | $9.00 | $12.88 | 43.11% | Buy |
| NARI | Inari Medical | $49.75 | $66.11 | 32.88% | Buy |
| INSP | Inspire Medical Systems | $186.19 | $239.55 | 28.66% | Buy |
| OFIX | Orthofix Medical | $18.68 | $24.00 | 28.48% | - |
| SILK | Silk Road Medical | $27.49 | $30.58 | 11.24% | Buy |
| CVRX | CVRx | $14.77 | $16.33 | 10.56% | Buy |
| PODD | Insulet | $262.00 | $274.00 | 4.58% | Buy |
| MASI | Masimo | $169.12 | $161.83 | -4.31% | Buy |
| PEN | Penumbra | $240.49 | $224.85 | -6.50% | Buy |
| SWAV | ShockWave Medical | $334.75 | $258.17 | -22.88% | Hold |